DE69940157D1 - Anthrax-impfstoff - Google Patents

Anthrax-impfstoff

Info

Publication number
DE69940157D1
DE69940157D1 DE69940157T DE69940157T DE69940157D1 DE 69940157 D1 DE69940157 D1 DE 69940157D1 DE 69940157 T DE69940157 T DE 69940157T DE 69940157 T DE69940157 T DE 69940157T DE 69940157 D1 DE69940157 D1 DE 69940157D1
Authority
DE
Germany
Prior art keywords
impfstoff
anthrax
aureus
intoxication
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69940157T
Other languages
English (en)
Inventor
John S Lee
Peter Pushko
Michael D Parker
Jonathan F Smith
Susan L Welkos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
U S MEDICAL RES INST OF INFECT
US Medical Research Institute of Infectious Diseases
Original Assignee
U S MEDICAL RES INST OF INFECT
US Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S MEDICAL RES INST OF INFECT, US Medical Research Institute of Infectious Diseases filed Critical U S MEDICAL RES INST OF INFECT
Application granted granted Critical
Publication of DE69940157D1 publication Critical patent/DE69940157D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
DE69940157T 1998-07-10 1999-07-09 Anthrax-impfstoff Expired - Fee Related DE69940157D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
PCT/US1999/015568 WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine

Publications (1)

Publication Number Publication Date
DE69940157D1 true DE69940157D1 (en) 2009-02-05

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69941454T Expired - Fee Related DE69941454D1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung
DE69940157T Expired - Fee Related DE69940157D1 (en) 1998-07-10 1999-07-09 Anthrax-impfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69941454T Expired - Fee Related DE69941454D1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung

Country Status (7)

Country Link
US (2) US6632640B1 (de)
EP (2) EP1097213B1 (de)
AT (2) ATE443768T1 (de)
AU (2) AU761021B2 (de)
CA (2) CA2339355A1 (de)
DE (2) DE69941454D1 (de)
WO (2) WO2000002522A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
EP1097213B1 (de) * 1998-07-10 2009-09-23 U.S. Medical Research Institute of Infectious Diseases Impfstoff gegen staphylokokken-vergiftung
AU762813B2 (en) * 1998-08-13 2003-07-03 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
JP2002541934A (ja) 1999-04-16 2002-12-10 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 二重チャンバー式貯蔵器を備えている薬物供給装置
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) * 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
EP1453534A1 (de) 2001-12-05 2004-09-08 Bhatnagar, Rakesh Prozess zur herstellung eines nicht toxischen anthrax impfstoffes
AU2003224265A1 (en) * 2002-04-11 2003-10-27 Powderject Research Limited Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
EP1670505B1 (de) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna-promotor und anthrax-vakzine
WO2005086637A2 (en) 2004-02-11 2005-09-22 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
KR101508563B1 (ko) 2004-09-22 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
AU2006236910B2 (en) * 2005-04-11 2012-06-07 Purdue Research Foundation Vaccine against pandemic strains of influenza viruses
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
EP2185190B1 (de) 2007-08-31 2015-06-24 University Of Chicago Verfahren und zusammensetzungen zur immunisierung gegen durch staphylokokken vermittelte lungenerkrankungen und -leiden
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2012170097A2 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
EP2844275B1 (de) 2012-04-26 2020-05-13 University of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
JP6632974B2 (ja) * 2013-06-19 2020-01-22 インテグレイテッド バイオセラピューティクス，インコーポレイテッド フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物
EA201891601A1 (ru) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
CA3069747A1 (en) 2017-07-27 2019-01-31 Mohammad Javad Aman Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
MX2021013908A (es) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Tratamiento para el cáncer.
EP4038091A1 (de) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus-peptide und verfahren zur verwendung
CA3170369A1 (en) 2020-03-05 2022-04-14 Michal Shahar Methods and compositions for treating cancer with immune cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681341B2 (en) * 1992-01-28 1997-08-28 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
EP0814154B1 (de) * 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Rekombinante Alphavirus-Vektoren
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
EP1055429A4 (de) * 1998-02-15 2004-09-08 Juridical Foundation Neue vorbeugungsmedizin/heilmittel für immunopathien
CA2336554A1 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
EP1097213B1 (de) * 1998-07-10 2009-09-23 U.S. Medical Research Institute of Infectious Diseases Impfstoff gegen staphylokokken-vergiftung
AU762813B2 (en) * 1998-08-13 2003-07-03 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
WO2000034445A2 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine

Also Published As

Publication number Publication date
US7374931B2 (en) 2008-05-20
US6632640B1 (en) 2003-10-14
WO2000002523A2 (en) 2000-01-20
WO2000002522A2 (en) 2000-01-20
AU5667399A (en) 2000-02-01
ATE418612T1 (de) 2009-01-15
CA2339355A1 (en) 2000-01-20
US20040009183A1 (en) 2004-01-15
AU761021B2 (en) 2003-05-29
EP1097212A2 (de) 2001-05-09
ATE443768T1 (de) 2009-10-15
DE69941454D1 (de) 2009-11-05
EP1097212B1 (de) 2008-12-24
WO2000002522A3 (en) 2000-10-12
WO2000002523A9 (en) 2000-07-27
EP1097213B1 (de) 2009-09-23
WO2000002523A3 (en) 2000-11-23
AU758019B2 (en) 2003-03-13
CA2337966A1 (en) 2000-01-20
AU5542699A (en) 2000-02-01
WO2000002522A9 (en) 2001-04-05
EP1097213A2 (de) 2001-05-09

Similar Documents

Publication Publication Date Title
DE69940157D1 (en) Anthrax-impfstoff
EP2196472A3 (de) Zusammensetzungen und Verfahren zur Auslösung einer Immunantwort auf Basis Alphavirus-Vektoren-Systeme
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
WO2002007742A8 (en) Bacteriophage having multiple host range
EA200100565A1 (ru) Новые стрептококковые антигены
ATE376587T1 (de) Granulat mit hoher schlagfestigkeit
WO2000002524A3 (en) Botulinum neurotoxin vaccine
HK1065789A1 (en) Oxazolidinone and/or isoxazoline derivatives as antibacterial agents.
HUP0002662A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
WO2001098460A3 (en) Fusion proteins of mycobacterium tuberculosis
DE68908183T2 (de) Thermophile alginat lyase aus bacillus stearothermophilus nrrlb-18394.
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO2005009378A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
GB9806762D0 (en) Treatment and diagnosis of staphylococcal infections
WO2002034773A3 (en) Streptococcal genes
AU2001232513A1 (en) An industrial robot with an actuated brake system, which cooperate with the robot's control system
AU2002218383A1 (en) Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant
AU2001275498A1 (en) Encryption system based on crossed inverse quasigroups
WO2003093416A3 (en) Protective antigens for the control of ixodes species infestations
AU2001251162A1 (en) Hair conditioning composition comprising vinylpyrrolidone copolymer
WO2001077365A3 (en) Antimicrobial methods and materials
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee